Barclays Reiterates an 'Overweight' on ARIAD Pharmaceuticals (ARIA); Ponatinib Demonstrated Acceptable Safety Profile

Go back to Barclays Reiterates an 'Overweight' on ARIAD Pharmaceuticals (ARIA); Ponatinib Demonstrated Acceptable Safety Profile